| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt KE O'Reilly, F Rojo, QB She, D Solit, GB Mills, D Smith, H Lane, ... Cancer research 66 (3), 1500-1508, 2006 | 3025 | 2006 |
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer A Carracedo, L Ma, J Teruya-Feldstein, F Rojo, L Salmena, A Alimonti, ... The Journal of clinical investigation 118 (9), 3065-3074, 2008 | 1698 | 2008 |
| Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells MA Molina, J Codony-Servat, J Albanell, F Rojo, J Arribas, J Baselga Cancer research 61 (12), 4744-4749, 2001 | 1105 | 2001 |
| Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer M Scaltriti, F Rojo, A Ocaña, J Anido, M Guzman, J Cortes, S Di Cosimo, ... Journal of the National Cancer Institute 99 (8), 628-638, 2007 | 1085 | 2007 |
| Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five … J Baselga, D Rischin, M Ranson, H Calvert, E Raymond, DG Kieback, ... Journal of clinical oncology 20 (21), 4292-4302, 2002 | 1025 | 2002 |
| PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization I Shin, FM Yakes, F Rojo, NY Shin, AV Bakin, J Baselga, CL Arteaga Nature medicine 8 (10), 1145-1152, 2002 | 1000 | 2002 |
| A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition T Vincent, EPA Neve, JR Johnson, A Kukalev, F Rojo, J Albanell, ... Nature cell biology 11 (8), 943-950, 2009 | 804 | 2009 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 795 | 2017 |
| Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non–small-cell lung cancer and other solid … RS Herbst, AM Maddox, ML Rothenberg, EJ Small, EH Rubin, J Baselga, ... Journal of Clinical Oncology 20 (18), 3815-3825, 2002 | 766 | 2002 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 697 | 2017 |
| Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors J Tabernero, F Rojo, E Calvo, H Burris, I Judson, K Hazell, E Martinelli, ... Journal of Clinical Oncology 26 (10), 1603-1610, 2008 | 658 | 2008 |
| Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Albanell, F Rojo, S Averbuch, A Feyereislova, JM Mascaro, R Herbst, ... Journal of Clinical Oncology 20 (1), 110-124, 2002 | 648 | 2002 |
| High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene A Bruna, RS Darken, F Rojo, A Ocaña, S Peñuelas, A Arias, R Paris, ... Cancer cell 11 (2), 147-160, 2007 | 599 | 2007 |
| Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors A O'Donnell, S Faivre, HA Burris III, D Rea, V Papadimitrakopoulou, ... Journal of Clinical Oncology 26 (10), 1588-1595, 2008 | 578 | 2008 |
| Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer J Baselga, J Albanell, A Ruiz, A Lluch, P Gascón, V Guillém, S González, ... Journal of Clinical Oncology 23 (23), 5323-5333, 2005 | 523 | 2005 |
| Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in … MV Dieci, N Radosevic-Robin, S Fineberg, G Van den Eynden, N Ternes, ... Seminars in cancer biology 52, 16-25, 2018 | 459* | 2018 |
| Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer AS Cazet, MN Hui, BL Elsworth, SZ Wu, D Roden, CL Chan, JN Skhinas, ... Nature communications 9 (1), 2897, 2018 | 401 | 2018 |
| Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma … J Albanell, J Codony-Servat, F Rojo, JM Del Campo, S Sauleda, J Anido, ... Cancer research 61 (17), 6500-6510, 2001 | 397 | 2001 |
| Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor … U Vanhoefer, M Tewes, F Rojo, O Dirsch, N Schleucher, O Rosen, ... Journal of Clinical Oncology 22 (1), 175-184, 2004 | 382 | 2004 |
| Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225) superiority over … P Matar, F Rojo, R Cassia, G Moreno-Bueno, S Di Cosimo, J Tabernero, ... Clinical cancer research 10 (19), 6487-6501, 2004 | 369 | 2004 |
Santiago Ramon y CajalHospital Vall d’HebronCorreu electrònic verificat a vhebron.net
